Ruihuachen Medical Secures Tens of Millions in Series A1 Funding to Accelerate AI-Powered Precision Radiotherapy Robotics Innovation

Recently, Beijing Ruihuachen Medical Technology Co., Ltd. (hereinafter referred to as “Ruihuachen Medical”) announced the successful completion of its A1 round financing, amounting to tens of millions of yuan. The round was led by CICC Huirong, under CICC Capital, with participation from institutions including Tianfeng Capital. The proceeds will be used to accelerate the in-depth innovative research and development of Ruihuachen Medical’s core product—the new generation of AI-enabled precise radiotherapy robots—and to inject strong momentum into its global industrial layout, marking a new stage in the independent innovation of China’s high-end large-scale medical equipment.

Beijing Ruihuachen Medical Technology Co., Ltd. was jointly established by leading medical robotics enterprise Tinavi (688277.SH), innovative minimally invasive oncology treatment platform Haijieya Medical, high-end medical device CDMO platform Beijing Medical Robot Industry Innovation Center, and U.S.-based innovative technology company Celestial Oncology. As a disruptor in the field of precision cancer radiotherapy, Ruihuachen Medical benefits from strong technical and market resources provided by its shareholders and focuses on the research and development of advanced radiation therapy technologies. The company has assembled a global team of top experts in medical physics, medical imaging, and artificial intelligence. Leveraging years of accumulated expertise in AI-enhanced Treatment Planning System (TPS) algorithms, it is committed to providing precise, efficient, safe, and intelligent next-generation radiotherapy solutions for cancer patients worldwide. Its independently developed 4π radiotherapy robotic system breakthroughly integrates a miniaturized high-dose-rate X-band linear accelerator, a multi-axis robotic platform, AI-enabled 4π non-coplanar treatment algorithms, and precise image guidance technology. This integration achieves precise beam delivery and significantly shortens treatment time, thereby realizing the goal of “enhancing efficacy while reducing toxicity” in radiation therapy. This disruptive innovation not only redefines the performance boundaries of radiotherapy equipment but also turns the clinical ideal of “precisely targeting tumor cells while maximizing protection of healthy tissues” into reality through the synergy between the robotic system and AI algorithms.

Mr. Wei Wensheng, General Manager of Beijing Ruihuachen Medical Technology Co., Ltd.stated: “We are deeply grateful for the trust and support of our investors! The evolution of radiation therapy technology is fundamentally driven by dual breakthroughs in physical constraints and biological effects. We stand at a critical inflection point for multidisciplinary innovation. Robotic technologies have overcome the traditional limitations on equipment motion degrees of freedom and precision, artificial intelligence algorithms enable real-time dynamic optimization of treatment plans, and miniaturized accelerator technologies have reshaped equipment form factors. Cancer treatment is transitioning toward digitalization and intelligence. Our intelligent 4π radiotherapy innovation system aligns perfectly with the development trends of precision medicine and is poised to lead precision radiotherapy into a new paradigm. This round of financing will accelerate the translation of technological achievements into clinical value, providing superior clinical solutions for clinical experts and cancer patients worldwide.”

Mr. Zhou Zhihui, Head of CICC Huirong under CICC Capitalstated: “Adhering to the investment philosophy of ‘investing early, investing in small-scale ventures, and investing in hard technology,’ we are delighted to participate in the A1 round of financing for Beijing Ruihuachen Medical Technology Co., Ltd. Ruihuachen Medical is a typical technology-driven company with internationally leading innovative technological expertise in the field of radiotherapy robotics. Cancer treatment represents a major global healthcare challenge, and Ruihuachen is poised to lead innovation in cancer therapies by integrating AI algorithms with robotic systems. We are highly optimistic about the company’s significant growth potential and will continue to firmly support its sustainable development. We remain committed to a clinical-oriented, technologically advanced development strategy, aiming to create outstanding products for the global market.”

Mr. Guan Jifeng, Founding Partner of Tianfeng Capitalstated: “We are deeply honored to invest in Ruihuachen Medical. Ruihuachen boasts an exceptional team, and its next-generation radiotherapy robot features unique advantages such as precise dose control, a broad treatment range, rapid treatment delivery, and significantly shortened treatment courses. It truly achieves precise irradiation from all angles without blind spots, representing a highly scarce, all-around precision radiotherapy solution. Innovative medical devices in China must be grounded in the core competitiveness of ‘Intelligent Manufacturing in China,’ fully leveraging the completeness of China’s industrial chain, the cost-efficiency advantages of system integration, the density of engineering innovation talent, and the scale effects formed by a unified national market. Tianfeng Capital will fully support Ruihuachen’s future development, looking forward to its early realization of the noble mission of promoting well-being and safeguarding the health of cancer patients.”